Single drug assessment in 2022 vs 2021 overview

IQVIA

Total number of single drug assessments



Oncology vs Non-oncology



- HTA publications increased by 3% in 2022 vs 2021. Oncology publications increased by 13% while non-oncology decreased by 4%
- France's HAS remains the agency with the highest number of assessments (322), and with 15% growth compared to 2021 while HTA reports in Singapore increased from 19 in 2021 to 133 in 2022

Recommendation types 2022 vs 2021



- Negative recommendations increased by 15% in 2022

Main rejection key drivers

Clinical & Economic



- Lack of direct comparator and cost-effectiveness remain the most frequently mentioned critiques on negative decisions.
- Heterogeneity among studies has moved up into the top-3 clinical decision drivers

EU4 + UK, Canada & Australia



- 2022 has brought a positive change for Spain due to reforms in the IPT's process. On the other hand, the starting of the process of reconstruction of AIFA in Italy has impacted the process in a negative way.
- The decrease in Canada and Germany cannot be explained by a change in regulatory marketing authorisations and may only be temporary
- What will the future bring? Contact us to learn more → https://www.iqvia.com/form-pages/demo

Source: IQVIA HTA Accelerator.

All SDAs from January till December 2022 compared to data from January 2021 to December 2021. We assume 12 months delay between regulatory decisions and HTA recommendations on average.

Abbreviations: SDA = Single drug assessment;; HAS: Haute Autorité de Santé; IPT: Theraeutic Positioning Information; AIFA: Agenzia Italiana del Farmaco.